ESSA Pharma Inc.·4

Jan 17, 8:57 PM ET

Virsik Peter 4

4 · ESSA Pharma Inc. · Filed Jan 17, 2024

Insider Transaction Report

Form 4
Period: 2024-01-16
Virsik Peter
Chief Operating Officer
Transactions
  • Sale

    Common Shares

    2024-01-16$10.01/sh1,718$17,19714,022 total
  • Exercise/Conversion

    Common Shares

    2024-01-16$3.23/sh+1,718$5,54915,740 total
  • Exercise/Conversion

    Options

    2024-01-161,718968,282 total
    Exercise: $3.23From: 2023-11-07Exp: 2029-10-07Common Shares (1,718 underlying)
Footnotes (2)
  • [F1]Reflects a transaction effected pursuant to Mr. Virsik's 10b5-1 trading plan. The Rule 10b5-1 trading plan was entered into on August 31, 2023.
  • [F2]The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION